Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Rating of “Moderate Buy” from Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has received a consensus rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $55.00.

Several equities analysts have commented on PTHS shares. Piper Sandler began coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They issued an “overweight” rating and a $48.00 price target for the company. Roth Mkm decreased their price objective on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Oppenheimer raised their target price on Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Finally, Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th.

Hedge Funds Weigh In On Pelthos Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Ikarian Capital LLC boosted its position in shares of Pelthos Therapeutics by 309.5% during the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after purchasing an additional 193,307 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Pelthos Therapeutics during the fourth quarter worth approximately $343,000. Boothbay Fund Management LLC lifted its holdings in shares of Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after purchasing an additional 59,435 shares in the last quarter. J. Goldman & Co LP acquired a new stake in Pelthos Therapeutics in the 4th quarter valued at $2,418,000. Finally, Cantor Fitzgerald L. P. acquired a new stake in Pelthos Therapeutics in the 4th quarter valued at $1,085,000. 77.96% of the stock is currently owned by institutional investors.

Pelthos Therapeutics Stock Performance

Shares of NYSEAMERICAN PTHS opened at $20.40 on Wednesday. The business’s 50-day simple moving average is $22.86. Pelthos Therapeutics has a 12 month low of $9.00 and a 12 month high of $54.29. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.15 and a current ratio of 2.05. The firm has a market capitalization of $68.54 million, a P/E ratio of -0.98 and a beta of 3.93.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).